French ocular disease specialist SparingVision has completed a €44.5m financing to help advance its gene therapy approach to tackling retinitis pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide.
The round was led by 4BIO Capital and the University of Pittsburgh Medical Center's UPMC Enterprises, and included France's Jeito...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
